This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Press Release

Rebranding: ITG Isotope Technologies Garching GmbH will become ITM Medical Isotopes GmbH

ITM’s subsidiary ITG Isotope Technologies Garching GmbH to be incorporated by name under the ITM family brand

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, today announced the change of name of its subsidiary ITG Isotope Technologies Garching GmbH. With effect from May 28, 2020, the company responsible specifically for the production of medical isotopes within the ITM Group will operate under the name ITM Medical Isotopes GmbH. The background to the decision is to present a uniform external image of the ITM group of companies, which, alongside ITM Medical Isotopes GmbH, includes among others the highly specialized companies ITM Oncologics GmbH and ITM Solucin GmbH.

The change of name will have no other impact on business partners, customers and staff. The legal form of the company and the ownership structure will remain unchanged. The fields of activity of radioisotope production, the product portfolio and all contracts concluded up to the rebranding will remain unchanged under the new company name. The head office address, the commercial register number and all known contact partners will remain unchanged.
ITG Isotope Technologies Garching GmbH, or ITM Medical Isotopes GmbH, is a 100% subsidiary of ITM Isotopen Technologien München AG. Over the course of the company’s 16-year history, from a start-up housed on the Technical University of Munich (TUM) site, ITM has established itself as a worldwide biotechnology and radiopharmaceutical group of companies in Targeted Radionuclide Therapy with a global distribution network. ITM develops, produces and distributes radiopharmaceuticals and medical radioisotopes for the diagnosis and therapy of cancer. The current product portfolio and focus of research includes targeted candidates for the treatment of neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor ? positive tumors such as lung, ovarian or breast cancer.

“We are proud of everything that we have managed to achieve jointly as the ITM group of companies over the past 16 years. We now supply hospitals, and hence patients, worldwide with our radiopharmaceuticals and medical radioisotopes for targeted cancer therapy,” says Steffen Schuster, CEO of ITM. “The pooling of our subsidiaries’ expertise will now also be reflected nominally by the unification under the ITM family brand. This will strengthen our market position and will allow all business areas to benefit equally from our first-class reputation as an international biotechnology and radiopharmaceutical group of companies,” adds Steffen Schuster, CEO of ITM.

                                                                                                                            - End -

 

ITM Isotopen Technologien München
ITM Isotopen Technologien München AG is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor ? positive tumors such as lung, ovarian or breast cancer. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
For more information please visit: www.itm.ag


Contact
Nicola Scharrer
Head of Marketing & Communications
Phone: +49 89 3298986-151
Email: Nicola.Scharrer(at)itm.ag
 

ITM Isotopen Technologien München AG
Executive Board: Steffen Schuster (CEO), Thomas Dürre (CFO)  -  Supervisory Board: Udo J Vetter (Chairman)  -  Registered Office: Garching/Munich
Commercial Register 154 944, District Court of Munich  -  Phone: +49 (0)89 329 8986 600  -  Fax: +49 (0)89 329 8986 650  -  Email: info@itm.ag
VAT Number: DE813228901  -  Deutsche Bank München  -  IBAN: DE52680700300022816300  -  BIC: DEUTDE6FXXX